Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Article Details

Citation

Copy to clipboard

Kornerup HJ, Pedersen EB, Christensen NJ, Pedersen A, Pedersen G

Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Eur J Clin Pharmacol. 1979 Nov;16(5):305-10.

PubMed ID

520398 [ View in PubMed

]

Abstract

Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months. Furosemide in a fixed dose was employed as a basic antihypertensive agent throughout the study. Blood pressure was adequately controlled in only 6 patients. Mean body weight increased by 1.8 kg and there was a rise in body weight which was inversely correlated with the fall in standing mean blood pressure. The mean plasma noradrenaline concentration decreased from 0.30 to 0.20 ng/ml, whereas plasma adrenaline did not change significantly. Plasma renin activity and aldosterone concentration varied greatly, but the mean values did not change significantly. Change in body weight was correlated inversely with changes in plasma noradrenaline and renin. The results suggest that labetalol, through its combined alpha- and beta-adrenergic receptor blocking action, induces a rise in body weight, probably due to sodium and fluid retention, which partly counterbalances the antihypertensive effect of labetalol, and partly modifies both renin and sympathetic nervous activity.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Labetalol	Approved	Noradrenaline	decreased	Labetalol decreases the level of Noradrenaline in the blood